Tag: AbYlink™

Antibody-drug conjugates (ADCs) have a well-known failure mode that has nothing to do with target selection. A company can identify an antibody with excellent affinity for a validated tumor antigen, attach a potent cytotoxic payload to it, and still watch the resulting conjugate underperform in the clinic, not because the biology was wrong, but because the molecule never distributed through the tumor the way the binding assay predicted it would. A new agreement between two Swiss life-sciences companies, Debiopharm and FluoSphera, is aimed squarely at that gap, the space between knowing an antibody binds its target and knowing what it does once it is actually inside a tumor.

Advancing Next-Generation Radiopharmaceuticals through Regio-Selective Conjugation

During the annual meeting for the American Association for Cancer Research (AACR) meeting held April 25 - 30, 2025 in Chicago, Illinois, Swiss-based Debiopharm presented comprehensive preclinical results for Debio 1562M (see ADC Drugmap) a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 being developed to be a potential first in class therapy in Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS).